

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/114057/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Li, Hui, Yang, Lu, Liu, Zhihai, Yin, Wenjuan, Liu, Dejun, Shen, Yingbo, Walsh, Timothy ORCID: <https://orcid.org/0000-0003-4315-4096>, Shao, Bing and Wang, Yang 2018. Molecular insights into functional differences between mcr-3- and mcr-1-mediated colistin resistance. Antimicrobial Agents and Chemotherapy , AAC.00366. 10.1128/AAC.00366-18 file

Publishers page: <http://dx.doi.org/10.1128/AAC.00366-18>
<<http://dx.doi.org/10.1128/AAC.00366-18>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17

3
4

5
6

7
8

9
1011
12

13

14

15

17

18 **ABSTRACT**

19 The global emergence of plasmid-mediated colistin resistance genes *mcr-1* and *mcr-3* has
20 threatened the role of the “last resort” drug colistin in the defense against infections caused
21 by multidrug-resistant Gram-negative bacteria. However, functional differences between
22 these two genes in mediating colistin resistance remains poorly understood. Protein sequence
23 alignment of MCR-3 and MCR-1 was therefore conducted in Clustal Omega to identify
24 sequence divergence. The molecular recognition of lipid A head group
25 phosphatidylethanolamine and MCR-3 enzyme was studied by homology modeling and
26 molecular docking, with the catalytic mechanism of MCR-3 also being explored. Thr277 in
27 MCR-3 was validated as the key amino acid residue responsible for the catalytic reaction
28 using site-directed mutagenesis and was shown to act as a nucleophile. Lipid A modification
29 induced by the MCR-3 and MCR-1 enzymes was confirmed by electrospray ionization
30 time-of-flight mass spectrometry. Far-UV circular dichroism spectra of the MCR-3 and
31 MCR-1 enzymes suggested that MCR-3 was more thermostable than MCR-1, with a melting
32 temperature of 66.19°C compared with 61.14°C for MCR-1. These data provided molecular
33 insight into the functional differences between *mcr-3* and *mcr-1* in conferring colistin
34 resistance.

35 **Keywords:** *mcr-3*, *mcr-1*, colistin resistance, homology modeling, phosphatidylethanolamine

36 INTRODUCTION

37 The emergence of multidrug-resistant Gram-negative pathogenic bacteria represents one
38 of the greatest global public health threats to date (1). Colistin is considered the last line of
39 defense against many of these clinical multidrug-resistant microorganisms (2, 3). The
40 antibacterial activity of colistin occurs as a result of an electrostatic interaction between the
41 α,γ -diaminobutyric acid residue of the positively-charged colistin and the phosphate groups
42 of the negatively-charged lipid A membrane. This destabilizes the lipopolysaccharide,
43 consequently increasing the permeability of the bacterial membrane. The colistin molecule
44 can then insert itself into the bacterial cell (2, 4). Modification of lipid A at the 1' and 4' head
45 group positions with phosphoethanolamine (PEA) or 4-amino-arabinose masks the
46 negatively-charged phosphate groups on the bacterial surface, thereby preventing the
47 interaction with cationic antimicrobial peptides such as colistin and polymyxin B (5).
48 Plasmid-mediated mobilized colistin resistance (MCR) enzymes, encoded by *mcr-1-5* (6-10),
49 are members of the PEA transferase family of proteins that decorate the lipid A head groups
50 of lipopolysaccharide with PEA, thereby conferring colistin resistance.

51 Recently, we described a new transferable plasmid-borne colistin resistance gene, *mcr-3*,
52 in an *Escherichia coli* isolate from pig feces (7). Subsequent epidemiological studies have
53 shown that, similar to *mcr-1*, *mcr-3* is widespread amongst various species of
54 *Enterobacteriaceae* and *Aeromonas* (11-14). Considering the spread and prevalence of these
55 two genes and their potential harm with regard to drug-resistant bacterial infections (15-17),
56 this study aimed to provide molecular insights into the functional differences between *mcr-3*
57 and *mcr-1*. Furthermore, the molecular mechanism underlying substrate binding by *mcr-3*

remains to be elucidated, and there is virtually no research deciphering its role in mediating colistin resistance. To address these issues, we carried out homology modeling and examined the molecular docking of MCR-3 with the substrate, L- α -phosphatidylethanolamine (L- α PEA), from *E. coli*. Identifying the catalytic mechanism and possible binding sites would aid in subsequent characterization of their biological characteristics. We also expressed and purified MCR-1 and MCR-3 and determined the thermal stability and secondary structure of these two lipid A PEA transferases. These functional comparisons showed that MCR-3 was more thermostable than MCR-1.

MATERIALS AND METHODS

Strains and plasmid construction

mcr-3 was cloned from the genomic DNA of *E. coli* plasmid pWJ1 by PCR using forward (5'-GGGAATTCCATATGATGCCTTCCCTTATAAAAAT-3') and reverse (5'-AAGGAAAAAAGCGGCCGCTTATTGAACATTACGACATTGAC-3') primers incorporating NdeI and NotI restriction sites at the N- and C-termini of the coding region, respectively. The resulting PCR products were digested with the corresponding restriction enzymes and ligated into expression vector pET28a, generating pET28a-*mcr-3*. *mcr-1* was then PCR-amplified from *E. coli* strain SHP45 genomic DNA using forward (5'-CATGCCATGGTGATGATGCAGCATACTTCTGTGTGGTACCGACG-3') and reverse (5'-CAAAGACCGCACCGCATTCATCCGCCTCGAGCGG-3') primers and cloned into plasmid pET28a to generate a high-copy expression vector with an N-terminal hexa-histidine tag (pET28a-*mcr-1*). The resulting recombinant MCR-3 and MCR-1 proteins contained a

80 tobacco etch virus protease cleavage site followed by a 6×His tag at the N terminus. The
81 calculated molecular masses of both the recombinant and cleaved monomeric MCR-3 and
82 MCR-1 proteins were ~60 kDa.

83 **Expression and purification of full-length MCR-3 and MCR-1**

84 For overexpression analyses, pET28a-*mcr-3* and pET28a-*mcr-1* were individually
85 transformed into *E. coli* BL21 (DE3) pLysS chemically-competent cells. The transformants
86 were then cultured in Luria Bertani (LB) medium supplemented with 50 µg/ml kanamycin at
87 37 °C with shaking for 3–4 h, or to an optical density at 600 nm (OD₆₀₀) of 0.5–0.6. Protein
88 expression was induced by the addition of 0.4 mM isopropyl-β-D-thiogalactopyranoside and
89 incubation at 18 °C for a further 20 h. Cells were harvested by centrifugation at 10,000 × *g*
90 for 10 min at 4 °C and then re-suspended in lysis buffer (50 mM sodium phosphate buffer, pH
91 8.0, containing 300 mM sodium chloride and 10 mM imidazole). Cell debris was removed by
92 centrifugation at 12,000 × *g* for 20 min at 4 °C, and membranes were collected by further
93 ultracentrifugation of the supernatant at 100,000 × *g* for 1 h at 4 °C using an ultracentrifuge
94 (Optima XE-100; Beckman Coulter, Brea, CA, USA). The resulting pellet was homogenized
95 in phosphate-buffered saline containing 1% *n*-dodecyl-β-D-maltoside (DDM) and solubilized
96 for 2 h at 4 °C on a rotational shaker at 50 rpm.

97 To purify the full-length MCR-1 and MCR-3, protein-containing supernatant was applied
98 to a Ni-NTA Superflow resin column (Qiagen, Hilden, Germany) equilibrated with binding
99 buffer (50 mM sodium phosphate, pH 7.5, 300 mM NaCl, 10 mM imidazole). The unbound
100 protein was washed from the column using washing buffer (50 mM sodium phosphate, pH
101 7.5, 300 mM NaCl, 20 mM imidazole), and the bound protein was eluted from the column

102 using elution buffer (50 mM sodium phosphate, pH 7.5, 300 mM NaCl, 200 mM imidazole,
103 0.05% (w/v) DDM). The eluent fractions were pooled and concentrated using a Vivaspin 20
104 centrifugal concentrator (MWCO 10 K; Sartorius, Göttingen, Germany) to a final
105 concentration of 5–10 mg/ml, as determined by the absorbance at 280 nm using a NanoDrop
106 2000c spectrophotometer.

107 **Isolation and mass spectrometry of lipid A**

108 The construction of *E. coli* strains W3110 (pUC19), W3110 (pUC19-*mcr-3*), and W3110
109 (pUC19-*mcr-1*) was described in our previous research (6, 7). Bacterial cultures (200 ml)
110 were incubated overnight in LB broth at 37 °C, and then cells were harvested by
111 centrifugation at 10,000 × *g* for 10 min. Lipid A was isolated by mild acidic hydrolysis
112 according to the method described previously by Hankins *et al.* (18). Lipid A was analyzed
113 using electrospray ionization quadrupole time-of-flight mass spectrometry (ESI-TOF/MS)
114 (Waters Synapt HR-MS, Milford, USA) in the negative-ion mode. The ESI-TOF/MS settings
115 were as follows: capillary voltage, 3.0 kV; sampling cone voltage, 30 V; source temperature,
116 100 °C; desolvation temperature, 500 °C; and desolvation gas (N₂), 600 l/h.

117 **Circular dichroism (CD) spectroscopy**

118 The far-UV spectra of MCR-1 and MCR-3 were measured at 20 °C on a CD
119 spectrophotometer (Jasco J-810, Tokyo, Japan) using a 1-mm path-length quartz cuvette. The
120 protein sample was diluted to a concentration of 0.2 mg/ml in 5 mM sodium phosphate (pH
121 7.0). CD data were collected every 1 nm using a 1-nm bandwidth in the 185–260-nm
122 wavelength region using an integration time of 1 s per step. Temperature-dependent CD
123 analysis was carried out at 220 nm with a temperature range of 10–90 °C and a rate of

124 1 °C/min to determine the melting temperature (T_m). The resulting spectra represented the
125 average of three accumulations and were buffer-baseline corrected with the signal-to-noise
126 ratio improved using the Savitzky-Golay method with a minimum convolution width of 5
127 data points. Analysis was conducted using Spectra Analysis software (version 1.53.07 for
128 Windows 95/NT; JASCO Corp., Tokyo, Japan).

129 **Molecular docking**

130 To provide an overview of full-length MCR-3, structural modeling was performed using
131 two approaches: the SWISS-MODEL workspace and the Modweb server (19, 20). Sequence
132 alignment of MCR-1, MCR-3, and EptA was conducted using Clustal Omega
133 (<http://www.ebi.ac.uk/Tools/msa/clustalo/>). The crystal structure of EptA (PDB ID: 5FGN)
134 was used for modeling by comparing the E-value and the structure total score. The EptA
135 structure was embedded into L- α PEA from *E. coli* using the Swiss-Model automated
136 homology-modeling server (<https://swissmodel.expasy.org/>). PROCHECK and ERRAT were
137 used to evaluate the optimized model protein structure. A Ramachandran plot was used to
138 illustrate the degree of rotation of the bonds between the α -carbon atoms and the carbonyl
139 carbon atoms of the peptide bond in a peptide or peptide structure of a protein. The degree of
140 rotation of the bond between the α -carbon atom and the nitrogen atom was mainly used to
141 indicate permitted and impermissible conformations of amino acid residues. The structure of
142 the protein after modeling was studied to further discuss the rationality of the model and
143 analyze the catalytic structure of MCR-3.

144 The interaction between the ligand and the MCR-3 protein structure, determined by
145 homology modeling, was investigated using AutoDock Tools 1.5.6, which generated the

146 pdbqt files used for molecular docking analysis. Molecular docking was completed using the
147 MolDesigner molecular simulation platform of AutoDock Vina (21). If the molecular docking
148 results produced unreasonable atomic contacts in the spatial structure, energy-optimized
149 methods were used to release these forces to stabilize the structure.

150 **Construction of *mcr-3* site-directed mutants**

151 To test the role of Thr277 in MCR-3, two different substitution-inducing mutations
152 (Thr277Ala and Thr277Ser) were introduced into *mcr-3* in pUC19-*mcr-3* using a
153 QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara,
154 CA, USA) as per the manufacturer's protocol using primers Thr277Ala-F
155 (5'-TCGTGTGGGACTGCAGCCGCTGTATCCGTCCCC-3') and Thr277Ala-R
156 (5'-GGGGACGGATACAGCGGCTGCAGTCCCACACGA-3'), and Thr277Ser-F
157 (5'-TCGTGTGGGACTGCAAGCGCTGTATCCGTCCCC-3') and Thr277Ser-R
158 (5'-GGGGACGGATACAGCGCTTGCAGTCCCACACGA-3'), respectively. These primers
159 introduced an ACC (coding for threonine) to GCC (coding for alanine) or AGC (coding for
160 serine) mutation at residue 277 of MCR-3. Recombinant plasmids containing wild-type *mcr-3*
161 or each of the two mutations (Thr277Ala and Thr277Ser) were then transformed into host *E.*
162 *coli* strain DH5 α . Sequencing of the complete *mcr-3* genes from each of the transformants
163 was conducted to ensure no extraneous mutations occurred. Minimum inhibitory
164 concentrations (MICs) of colistin and polymyxin for *E. coli* DH5 α , DH5 α (pUC19), DH5 α
165 (pUC19-*mcr-3*), and each of the site-directed mutants were measured by the broth
166 microdilution method according to the Clinical and Laboratory Standards Institute guidelines
167 (22).

168

169 **RESULTS AND DISCUSSION**170 **Lipid A modification mediated by *mcr-3* and *mcr-1* confirmed by ESI-TOF/MS**

171 *mcr-3* and *mcr-1* encode PEA transferases that mediate colistin resistance in a variety of
172 bacterial species, including *E. coli*, *Aeromonas veronii*, *Salmonella enterica* serovar
173 Typhimurium, *Klebsiella pneumoniae*, and *Citrobacter freundii* (12-14). In this study, lipid A
174 was extracted from recombinant *E. coli* strains W3110 (pUC19-*mcr-3*), *E. coli* W3110
175 (pUC19-*mcr-1*), and *E. coli* W3110 (pUC19) and the lipid spectra was analyzed by
176 ESI-TOF/MS. ESI-MS/MS spectra showed that lipid A from *E. coli* W3110 (pUC19) had a
177 prominent peak at m/z 1797.10 (Fig. 1A). Upon the addition of a PEA molecule (123 Da) to
178 the bis-phosphorylated hexa-acylated lipid A in both *E. coli* W3110 (pUC19-*mcr-1*) and
179 W3110 (pUC19-*mcr-3*), the peak shifted to m/z 1920 (i.e., $1797 + 123$) (Fig. 1B, C). Previous
180 research has shown that MCR-1 can transfer PEA from phosphatidylethanolamine to the
181 negatively-charged phosphate groups of lipid A, resulting in decreased affinity for colistin (23,
182 24). The proposed lipid A modification catalyzed by MCR-3 is shown in Fig. 1D. Thus, we
183 confirmed that MCR-3, like MCR-1, could modify lipid A on the bacterial cell membrane,
184 thereby mediating colistin resistance.

185 **Comparison of the models of full-length MCR-3 and MCR-1**

186 Four proteins, EptA (PDB:5FGN), LptA (PDB:4KAY and 4KAV), and MCR-1
187 (PDB:5K4P), were aligned to select a template for homology modeling. In general, protein
188 crystals with higher total scores or E-values less than $1e^{-5}$ can be considered for use as
189 templates. Both the SWISS-MODEL workspace and the Modweb server automatically

190 selected full-length EptA as the template for homology modeling and returned similar
191 modeling results (Table 1 and Fig. 2). Template 5FGN had the highest score with the target
192 sequence, with a sequence identity of 39%. Templates 4KAY and 4KAV reached 44%
193 sequence identity but the sequence coverage was only 60% (Table 1), indicating that they
194 were missing part of the structure and were not suitable as templates for building a complete
195 protein model. 5K4P only showed 35% sequence identity with MCR-3.

196 The structure of MCR-3 was composed of two folded domains: an N-terminal
197 transmembrane (TM) domain and a C-terminal catalytic domain. The TM domain consisted
198 of five membrane-spanning α -helices (residues 1–212) connected to the catalytic domain via
199 a bridging helix (Fig. 3). There were multiple lysine and histidine residues on the membrane
200 surface, and these basic amino acids could improve the stability of MCR-3 on the membrane
201 to a certain extent. The soluble cytoplasmic domain had a similar structure to the hydrolase
202 active site (5). The Zn^{2+} ions bound to the active site and formed tetrahedral coordination
203 structures with Glu238, Thr277, Asp450, and His451, with distances of 1.9, 2.2, 2.0, and 1.9
204 Å, respectively. Thr277 was the key amino acid responsible for the catalytic reaction, acting
205 as a nucleophile. In addition, disulfide bonds formed by five pairs of cysteines were
206 distributed in this region, which stabilized the structure of the region as a whole. Furthermore,
207 conserved residue Thr285 in the MCR-1 catalytic domain structure is believed to act as the
208 acceptor for the PEA group during the transfer reaction (25-27). MCR-1 transfers PEA to
209 lipid A, which is located in the nearby pocket consisting of Thr283, Ser284, Tyr287, Pro481,
210 and Asn482 (28). It was demonstrated that a threonine residue (Thr285 for MCR-1 and
211 Thr277 for MCR-3) in the catalytic domain played an important role in mediating colistin

212 resistance. The rationality of the MCR-3 protein homology modeling and the structural
213 integrity of the catalytic active center proved the reliability of the structure and could be used
214 for subsequent molecular docking analyses to explore the catalytic mechanism of MCR-3.

215 **Catalytic reaction mechanism of MCR-3 deciphered by molecular docking**

216 Prior to the catalytic transfer of PEA by MCR-3, the side-chain hydroxyls of the
217 catalytically-active Thr277 lose their hydrogen protons, forming oxyanions by nucleophilic
218 attack. In the MCR-3 model, the amino acid residues Glu111, His380, and His463 could
219 receive the hydrogen proton in the vicinity of the catalytic center. The distances between the
220 oxygen of Thr277 and the three residues were 5.3, 5.4, and 5.1 Å, respectively. It would be
221 difficult to directly transfer the proton from these spatial distances. However, there was a
222 water molecule between these three amino acids, which was not present in the catalytic center
223 of the general template crystal structure of EptA. The hydrogen protons of Thr277 are
224 therefore likely to be transferred by the water molecule to the three residues. The results of
225 molecular docking analysis showed that PEA could bind to the catalytically-active cavity of
226 MCR-3, with a binding energy of -7.1 kcal/mol. The main driving power of PEA binding
227 was the “head” hydrogen and the “tail” hydrophobicity (Fig. 4). The PEA moiety at the head
228 of L- α PEA formed a hydrogen bond network with Glu111, Thr277, Ala278, His451, and
229 His463. These hydrogen bonds would stabilize the PEA head in the catalytic center of the
230 MCR-3 enzyme, which would be favorable for the subsequent catalytic reaction. The alkyl
231 chain at the terminus of L- α PEA extended into the transmembrane region of the MCR-3
232 protein and formed strong hydrophobic bonds with the Ile84, Thr88, Val94, Asn103, Ile104,
233 Ala112, Tyr115, Leu116, Ile120, and Leu462 residues. This hydrophobic interaction would

234 enhance the stable binding of the PEA substrate to the active cavity of the MCR-3 enzyme.

235 We further analyzed the binding conformations and found that the distance between the
236 O1 of the L- α -PEA molecule and Zn^{2+} in the catalytic center was 2.7 Å, while the distance
237 between the P atom of the phosphoric acid group and the O atom of the Thr277 hydroxyl was
238 3.1 Å. This finding demonstrated that the two pairs of atoms might be separated by the
239 electrostatic interactions of the O1-Zn and P-O covalent bonds, respectively. It was also
240 noteworthy that the O2 of the terminal alkyl side chain in L- α PEA formed a hydrogen bond
241 with His463 at a distance of 2.2 Å, indicating that hydrogen protons on His463 might be
242 transferred to the O2 of L- α PEA. The P-O2 bond then broke to form a product. We
243 concluded that the hydrogen proton of Thr277 was likely to be transferred to the His463
244 residue via a water molecule. The protonated His463 could then provide hydrogen protons to
245 the alkyl chains at the ends of L- α PEA to complete the entire catalysis reaction.

246 Next, we speculated on the possible mechanism of the MCR-3-catalyzed reaction (Fig. 5).
247 The reaction was divided into two main steps: (1) the hydrogen protons on the
248 catalytically-active Thr277 side chain hydroxyls in MCR-3 were transferred to the nitrogen of
249 the His466 residue side chains via water molecules. Thr277 was further activated to become a
250 nucleophilic attacking group, and the protonated His463 residue was subsequently involved
251 in the reaction as a hydrogen proton donor. At the same time, the carboxylate of Glu238
252 would attract the carboxyl hydrogen proton of Asp321 to Glu238, leaving the catalytic center
253 electrically neutral. (2) During L- α PEA binding to the catalytically-active site, the O1 of the
254 phosphate group coordinates with Zn to form a coordinate covalent bond. P forms a covalent
255 bond with the hydroxyl oxygen of Thr277, and the covalently-linked bonds between the O2

256 in the terminal alkyl side chain and P were broken, forming the Thr-PEA complexes. The
257 Thr-PEA complex is a positively-charged group, which would result in a decrease in the
258 negative charge of the bacterial outer membrane, reducing the absorbance capacity of the
259 bacterium for positively-charged colistin, which in turn leads to bacterial resistance to
260 colistin.

261 **Mutation of Thr277 decreases MCR-3 function**

262 As Thr277 was considered to be the key amino acid responsible for the catalytic reaction,
263 mutation of this amino acid would be expected to decrease the functional abilities of MCR-3.
264 To test this hypothesis, we constructed two strains carrying plasmid pUC19-*mcr-3* containing
265 mutations within MCR-3 (Thr277Ala and Thr277Ser). We then measured the MICs of
266 colistin and polymyxin for these strains in comparison with the wild-type. The MIC of
267 colistin for the strain containing pUC19-*mcr-3* was 4.0 $\mu\text{g/ml}$, compared with 0.5 $\mu\text{g/ml}$ for
268 the control strain containing empty plasmid (pUC19). The strain containing a Thr277Ala
269 substitution in MCR-3 had a colistin MIC similar to that of the control (0.5–1 $\mu\text{g/ml}$, Table 2),
270 while the Thr277Ser mutation resulted in a 4-fold decrease in the MICs of colistin and
271 polymyxin compared with the *E. coli* DH5 α (pUC19-*mcr-3*) strain (Table 2). Taken together,
272 site-directed mutagenesis verified the importance of the Thr277 residue to the catalytic
273 activity of lipid A.

274 **MCR-3 shows greater thermostability than MCR-1**

275 In the absence of high-resolution structures, CD is the method of choice for providing
276 secondary structural information for proteins in solution (29). To explore the resistance
277 mechanism of the novel MCR-3 protein and compare its structure and function with MCR-1,

278 we expressed and purified the full-length MCR-3 protein. Characterization of the secondary
279 structures of MCR-1 and MCR-3 was then achieved using CD spectra. The normalized CD
280 spectra of MCR-1 and MCR-3 from 185–260 nm are shown in Fig. 6A. MCR-3 and MCR-1
281 were well-folded, structured proteins and presented similar structural properties with regard
282 to α -helical and β -sheet content from the deconvolution. We also compared the thermal
283 stability of MCR-3 and MCR-1 using temperature-dependent CD. As a result, melting
284 temperatures of approximately 66.19 °C and 61.14 °C were obtained for MCR-3 and MCR-1,
285 respectively. The CD results showed clear differences in the thermal stabilities of the two
286 proteins (Fig. 6B) and revealed that MCR-3 was more thermostable than MCR-1 ($p < 0.05$).
287 The differences in stability with respect to thermal denaturation, with >5 °C difference in
288 melting temperature, implied that the catalytic properties of the two proteins in mediating
289 bacterial resistance might differ. Therefore, further investigation should focus on the
290 association of thermodynamic stability and enzymatic function of different MCR proteins.

291

292 ACKNOWLEDGMENTS

293 This work was supported by the National Natural Science Foundation of China (Grant No.
294 31602107 and 81661138002), Capital's Funds for Health Improvement and Research (Grant
295 No. 2018-4-3017), and Medical Research Council grant DETER-XDR-CHINA
296 (MR/P007295/1).

297

298 CONFLICTS OF INTEREST

299 None.

300

301 **References**

- 302 1. Nation RL, Li J. 2009. Colistin in the 21st century. *Curr Opin Infect Dis* 22:535-43.
- 303 2. Trimble MJ, Mlynářčík P, Kolář M, Hancock REW. 2016. Polymyxin: alternative
304 mechanisms of action and resistance. *Cold Spring Harb Perspect Med* 6:pii: a025288.
- 305 3. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. *Clin*
306 *Microbiol Rev* 21:449-465.
- 307 4. Poire L, Jayol A, Nordmann P. 2017. Polymyxins: antibacterial activity, susceptibility
308 testing, and resistance mechanisms encoded by plasmids or chromosomes. *Clin*
309 *Microbiol Rev* 30:557-596.
- 310 5. Anandan A, Evans GL, Condic-Jurkic K, O'Mara ML, John CM, Phillips NJ, Jarvis
311 GA, Wills SS, Stubbs KA, Moraes I, Kahler CM, Vrielink A. 2017. Structure of a
312 lipid A phosphoethanolamine transferase suggests how conformational changes
313 govern substrate binding. *Proc Natl Acad Sci U S A* 114:2218-2223.
- 314 6. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, Doi Y, Tian G, Dong B,
315 Huang X, Yu L-F, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu J-H,
316 Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism *MCR-1*
317 in animals and human beings in China: a microbiological and molecular biological
318 study. *Lancet Infect Dis* 16:161-168.
- 319 7. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, Zhang R, Walsh TR, Shen J, Wang Y.
320 2017. Novel plasmid-mediated colistin resistance gene *mcr-3* in *Escherichia coli*.
321 *MBio* 8:e00543-17.
- 322 8. Xavier BB, Lammens C, Ruhel R, Kumar-Singh S, Butaye P, Goossens H,
323 Malhotra-Kumar S. 2016. Identification of a novel plasmid-mediated
324 colistin-resistance gene, *mcr-2*, in *Escherichia coli*, Belgium, June 2016. *Euro*
325 *Surveill* 21:1-6.
- 326 9. Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B. 2017.
327 Identification of a novel transposon-associated phosphoethanolamine transferase gene,
328 *mcr-5*, conferring colistin resistance in *d*-tartrate fermenting *Salmonella enterica*
329 subsp. *enterica* serovar Paratyphi B. *J Antimicrob Chemother* 72:3317-3324.
- 330 10. Carattoli A, Villa L, Feudi C, Curcio L, Orsini S, Luppi A, Pezzotti G, Magistrati CF.
331 2017. Novel plasmid-mediated colistin resistance *mcr-4* gene in *Salmonella* and
332 *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill*
333 22:pii:30589.
- 334 11. Litrup E, Kiil K, Hammerum AM, Roer L, Nielsen EM, Torpdahl M. 2017.
335 Plasmid-borne colistin resistance gene *mcr-3* in *Salmonella* isolates from human
336 infections, Denmark, 2009-17. *Euro Surveill* 22:pii=30587.
- 337 12. Ling Z, Yin W, Li H, Zhang Q, Wang X, Wang Z, Ke Y, Wang Y, Shen J. 2017.
338 Chromosome-mediated *mcr-3* variants in *Aeromonas veronii* from chicken meat.
339 *Antimicrob Agents Chemother* 61:pii:e01272-17.
- 340 13. Liu L, Feng Y, Zhang X, McNally A, Zong Z. 2017. A new variant of *mcr-3* in an
341 extensively drug-resistant *Escherichia coli* clinical isolate carrying *mcr-1* and

- 342 *bla*_{NDM-5}. Antimicrob Agents Chemother 61:pii:e01757-17.
- 343 14. Roer L, Hansen F, Stegger M, Sonksen UW, Hasman H, Hammerum AM. 2017.
- 344 Novel *mcr-3* variant, encoding mobile colistin resistance, in an ST131 *Escherichia*
- 345 *coli* isolate from bloodstream infection, Denmark, 2014. Euro Surveill 22:pii=30584.
- 346 15. Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, Jin L, Zhang Q, Liu Y,
- 347 Rieux A, Dorai-Schneiders T, Weinert LA, Iqbal Z, Didelot X, Wang H, Balloux F.
- 348 2018. The global distribution and spread of the mobilized colistin resistance gene
- 349 *mcr-1*. Nat Commun 9:1179.
- 350 16. Zhang J, Chen L, Wang J, Butaye P, Huang K, Qiu H, Zhang X, Gong W, Wang C.
- 351 2018. Molecular detection of colistin resistance genes (*mcr-1* to *mcr-5*) in human
- 352 vaginal swabs. BMC Res Notes 11:143.
- 353 17. Del Bianco F, Morotti M, Pedna MF, Farabegoli P, Sambri V. 2018. Microbiological
- 354 surveillance of plasmid mediated colistin resistance in human *Enterobacteriaceae*
- 355 isolates in Romagna (Northern Italy): August 2016–July 2017. International Journal
- 356 of Infectious Diseases 69:96-98.
- 357 18. Hankins JV, Madsen JA, Needham BD, Brodbelt JS, Trent MS. 2013. The outer
- 358 membrane of Gram-negative bacteria: lipid A isolation and characterization. Methods
- 359 Mol Biol 966:239-258.
- 360 19. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, Kiefer F, Gallo
- 361 Cassarino T, Bertoni M, Bordoli L, Schwede T. 2014. SWISS-MODEL: modelling
- 362 protein tertiary and quaternary structure using evolutionary information. Nucleic
- 363 Acids Res 42:W252-8.
- 364 20. Eswar N. 2003. Tools for comparative protein structure modeling and analysis.
- 365 Nucleic Acids Res 31:3375-3380.
- 366 21. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of
- 367 docking with a new scoring function, efficient optimization, and multithreading. J
- 368 Comput Chem 31:455-461.
- 369 22. CLSI. 2015. Performance standards for antimicrobial disk and dilution susceptibility
- 370 tests for Bacteria isolated from animals: approved standard M31-A3. VET01S, 3rd
- 371 ed:128.
- 372 23. Gao R, Hu Y, Li Z, Sun J, Wang Q, Lin J, Ye H, Liu F, Srinivas S, Li D, Zhu B, Liu
- 373 YH, Tian GB, Feng Y. 2016. Dissemination and Mechanism for the *MCR-1* Colistin
- 374 Resistance. PLoS Pathog 12:e1005957.
- 375 24. Kelesidis T, Falagas ME. 2015. The safety of polymyxin antibiotics. Expert Opin
- 376 Drug Saf 14:1687-1701.
- 377 25. Hinchliffe P, Yang QE, Portal E, Young T, Li H, Tooke CL, Carvalho MJ, Paterson
- 378 NG, Brem J, Niumsup PR, Tansawai U, Lei L, Li M, Shen Z, Wang Y, Schofield CJ,
- 379 Mulholland AJ, Shen J, Fey N, Walsh TR, Spencer J. 2017. Insights into the
- 380 Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures
- 381 of the Catalytic Domain of MCR-1. Sci Rep 7:39392-39401.
- 382 26. Stojanoski V, Sankaran B, Prasad BV, Poirel L, Nordmann P, Palzkill T. 2016.
- 383 Structure of the catalytic domain of the colistin resistance enzyme MCR-1. BMC Biol
- 384 14:81-90.
- 385 27. Ma G, Zhu Y, Yu Z, Ahmad A, Zhang H. 2016. High resolution crystal structure of the

- 386 catalytic domain of MCR-1. Sci Rep 6:39540.
- 387 28. Wei P, Song G, Shi M, Zhou Y, Liu Y, Lei J, Chen P, Yin L. 2017. Substrate analog
388 interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated
389 transferable colistin resistance. FASEB J 32:1-18.
- 390 29. Micsonai A, Wien F, Kernya L, Lee YH, Goto Y, Refregiers M, Kardos J. 2015.
391 Accurate secondary structure prediction and fold recognition for circular dichroism
392 spectroscopy. Proc Natl Acad Sci U S A 112:E3095-103.

393

394 Figure Legends

395 FIG. 1 ESI-QTOF/MS analysis showing the PEA modification of bacterial lipid A

396 mediated by MCR-3 and MCR-1. (A) ESI-QTOF/MS spectrum of the negative ion of lipid
397 A extracted from the recombinant control strain *E. coli* W3110 (pUC19). Lipid A had a
398 prominent peak at m/z 1797.10 but no peak at m/z 1920, indicating no PEA modification. (B)
399 ESI-QTOF/MS spectrum of the negative ion of lipid A extracted from the recombinant
400 positive control strain *E. coli* W3110 (pUC19-*mcr-1*). A PEA molecule (123 Da) was added
401 to the bisphosphorylated hexa-acylated lipid A (m/z = 1920; i.e., 1797 + 123). (C)
402 ESI-QTOF/MS spectrum of lipid A extracted from the recombinant strain *E. coli* W3110
403 (pUC19-*mcr-3*). The peak observed at m/z 1920 was consistent with the addition of a single
404 PEA group (123 Da) to ions represented by the prominent peak at m/z 1797.2, corresponding
405 to dephosphorylated lipid A. (D) Reaction catalyzed by MCR-3.

406 FIG. 2 Multiple sequence alignment of MCR-3, MCR-1, and EptA conducted using

407 Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).

408 FIG. 3 Three-dimensional structure of MCR-3 generated by homology modeling. The


409 protein was shown as a gray strip model. The catalytic residues were shown as a stick model,
410 and Zn^{2+} ions were shown by a gray sphere. The numbers in red indicated the distance
411 between coordination bonds (Å).

412 **FIG. 4 Schematic showing the interaction between L- α PEA and the amino acids around**
413 **the active site of MCR-3.** (A) Hydrophobic residues were indicated by the green solid line
414 and green residue labels, while the black dashed line represented the hydrogen bond. (B)
415 Three-dimensional model of the binding between L- α PEA and the MCR-3 active site. The
416 protein was shown in gray, with interacting residues shown as a green stick model, L- α PEA
417 as a yellow stick model, and zinc ions in gray spheres, with black dotted lines indicating the
418 interaction and distance between the L- α PEA and MCR-3 molecules.

419 **FIG. 5 Proposed reaction mechanism of L- α PEA catalyzed by MCR-3.**

420 **FIG. 6 Secondary structure characterization of MCR-1 and MCR-3 by CD analysis.** (A)
421 Normalized CD spectra of MCR-1 and MCR-3. Data were obtained at 20 °C using 10 mM
422 phosphate buffer, with a protein concentration of $\sim 2.5 \mu\text{M}$. (B) Thermal stability melting
423 curves. Melting temperatures of MCR-1 and MCR-3 as determined by CD. MCR-1: 61.14 °C;
424 MCR-3: 66.19 °C.

FIG. 1



430 **FIG. 1 ESI-QTOF/MS analysis showing the PEA modification of bacterial lipid A**
431 **mediated by MCR-3 and MCR-1.** (A) ESI-QTOF/MS spectrum of the negative ion
432 of lipid A extracted from the recombinant control strain *E. coli* W3110 (pUC19).
433 Lipid A had a prominent peak at m/z 1797.10 but no peak at m/z 1920, indicating no
434 PEA modification. (B) ESI-QTOF/MS spectrum of the negative ion of lipid A
435 extracted from the recombinant positive control strain *E. coli* W3110 (pUC19-*mcr-1*).
436 A PEA molecule (123 Da) was added to the bisphosphorylated hexa-acylated lipid A
437 ($m/z = 1920$; i.e., $1797 + 123$). (C) ESI-QTOF/MS spectrum of lipid A extracted from
438 the recombinant strain *E. coli* W3110 (pUC19-*mcr-3*). The peak observed at m/z 1920
439 was consistent with the addition of a single PEA group (123 Da) to ions represented
440 by the prominent peak at m/z 1797.2, corresponding to dephosphorylated lipid A. (D)
441 Reaction catalyzed by MCR-3.





FIG. 2 Multiple sequence alignment of MCR-3, MCR-1, and EptA conducted using Clustal Omega (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).


445 **FIG. 3**

446

447 **FIG. 3 Three-dimensional structure of MCR-3 generated by homology modeling.**


448 The protein was shown as a gray strip model. The catalytic residues were shown as a
449 stick model, and Zn²⁺ ions were shown by a gray sphere. The numbers in red
450 indicated the distance between coordination bonds (Å).

451 **FIG. 4**




452 **FIG. 4 Schematic showing the interaction between L-αPEA and the amino acids**
 453 **around the active site of MCR-3.** (A) Hydrophobic residues were indicated by the
 454 green solid line and green residue labels, while the black dashed line represented the
 455 hydrogen bond. (B) Three-dimensional model of the binding between L-αPEA and the
 456 MCR-3 active site. The protein was shown in gray, with interacting residues shown as
 457 a green stick model, L-αPEA as a yellow stick model, and zinc ions in gray spheres,
 458 with black dotted lines indicating the interaction and distance between the L-αPEA
 459 and MCR-3 molecules.

461 **FIG. 5**



462

463 **FIG. 5 Proposed reaction mechanism of L-αPEA catalyzed by MCR-3.**

464 **FIG. 6**

465

466 **FIG. 6 Secondary structure characterization of MCR-1 and MCR-3 by CD analysis. (A)**

467 Normalized CD spectra of MCR-1 and MCR-3. Data were obtained at 20 °C using 10 mM

468 phosphate buffer, with a protein concentration of ~2.5 μ M. (B) Thermal stability melting

469 curves. Melting temperatures of MCR-1 and MCR-3 as determined by CD. MCR-1: 61.14 °C;

470 MCR-3: 66.19 °C.

471 **Tables**472 **Table 1** Multiple sequence alignment of the selected homology templates.

| | Template | Total score | E-value | Identity | Query cover | Resolution/ Å |
|-------|----------|-------------|---------|----------|-------------|---------------|
| MCR-3 | 5FGN | 408 | 7e-137 | 39% | 98% | 2.75 |
| | 4KAY | 310 | 2e-101 | 44% | 60% | 1.78 |
| | 4KAV | 301 | 5e-98 | 44% | 60% | 1.43 |
| | 5K4P | 305 | 6e-97 | 35% | 70% | 1.32 |

473 **Table 2** MIC values for colistin and polymyxin against *E. coli* strain DH5 α carrying the

474 wild-type *mcr-3* gene or either of the two mutation variants (Thr277Ala and Thr277Ser).

| <i>E. coli</i> DH5 α Strains | Colistin (μ g/ml) | Polymyxin (μ g/ml) |
|-------------------------------------|------------------------|-------------------------|
| DH5 α | 0.5 | 0.5 |
| pUC19 | 0.5 | 0.5 |
| pUC19- <i>mcr-3</i> | 4 | 4 |
| pUC19- <i>mcr-3</i> (Thr277Ala) | 0.5 | 0.5 |
| pUC19- <i>mcr-3</i> (Thr277Ser) | 1 | 1 |

475

476